ACME Laboratories (DHA:ACMELAB) Debt-to-Equity : 0.94 (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is ACME Laboratories Debt-to-Equity?

ACME Laboratories's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was BDT16,639 Mil. ACME Laboratories's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was BDT6,261 Mil. ACME Laboratories's Total Stockholders Equity for the quarter that ended in Mar. 2024 was BDT24,402 Mil. ACME Laboratories's debt to equity for the quarter that ended in Mar. 2024 was 0.94.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for ACME Laboratories's Debt-to-Equity or its related term are showing as below:

DHA:ACMELAB' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.56 Med: 0.75 Max: 0.94
Current: 0.94

During the past 8 years, the highest Debt-to-Equity Ratio of ACME Laboratories was 0.94. The lowest was 0.56. And the median was 0.75.

DHA:ACMELAB's Debt-to-Equity is ranked worse than
83.84% of 848 companies
in the Drug Manufacturers industry
Industry Median: 0.3 vs DHA:ACMELAB: 0.94

ACME Laboratories Debt-to-Equity Historical Data

The historical data trend for ACME Laboratories's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ACME Laboratories Debt-to-Equity Chart

ACME Laboratories Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Debt-to-Equity

Get a 7-Day Free Trial

0.76

0.84

0.76

0.74

0.89

ACME Laboratories Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.82	0.85	0.89	0.91	0.94

Competitive Comparison of ACME Laboratories's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, ACME Laboratories's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ACME Laboratories's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ACME Laboratories's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where ACME Laboratories's Debt-to-Equity falls into.

ACME Laboratories Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

ACME Laboratories's Debt to Equity Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(14599.132	+	6230.276)	/	23295.117
	=	0.89

ACME Laboratories's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(16639.291	+	6261.459)	/	24402.376
	=	0.94

ACME Laboratories (DHA:ACMELAB) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

ACME Laboratories Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of ACME Laboratories's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

ACME Laboratories (DHA:ACMELAB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » ACME Laboratories Ltd (DHA:ACMELAB) » Definitions » Debt-to-Equity

Traded in Other Exchanges

N/A

Address

1/4, Kallayanpur, Mirpur Road, Court de la ACME, Dhaka, BGD, 1207

Website

https://www.acmeglobal.com

ACME Laboratories Ltd is engaged in the manufacturing, marketing, and distribution of generic pharmaceutical products in Bangladesh. The company offers pharmaceutical, ayurvedic, herbal, nutraceutical products, and veterinary products. It produces various forms of dosage including tablet, capsule, dry syrup, cream, ointment, powder and injection among others.

ACME Laboratories (DHA:ACMELAB) Headlines

No Headlines